0.00Open0.07Pre Close0 Volume29 Open Interest3.00Strike Price0.00Turnover0.00%IV-84.63%PremiumJan 17, 2025Expiry Date16.98Intrinsic Value100Multiplier46DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma285.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Arqit Quantum Stock Discussion
H.C. Wainwright adjusted the firm's price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the recent reverse share split.
The firm believes the upcoming second half of 2024 results could be a potential catalyst for the shares.
Gapping up
$Poseida Therapeutics (PSTX.US)$' stock jumped over 200%. This happened because Roche, a Swiss company, is buying Poseida for up to $1.5 billion in cash.
Shares of weight-loss drug maker $Novo-Nordisk A/S (NVO.US)$ and $Eli Lilly and Co (LLY.US)$ rose 2.1% and 4.9% respectively on Tuesday as U.S. President Jo Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid...
Deutsche Bank's Chief Global Strategist, Binky Chadha, has put fort...
No comment yet